The pan-cancer patterns, immune correlations, and BUB1 interaction uncovered here provide a roadmap for targeting SGO1 in precision oncology, either as a standalone biomarker or in combination with immune/DNA-damaging therapies. This evidence concerns the gene BUB1 and cancer.